SAB Spotlight: Dr David Azria
David Azria, a renowned radiation oncologist, is a distinguished member of our Scientific Advisory Board (SAB). His expertise encompasses breast and urogenital cancers, including prostate, kidney, bladder, and testis cancers.
David Azria, a renowned radiation oncologist, is a distinguished member of our Scientific Advisory Board (SAB). His expertise encompasses breast and urogenital cancers, including prostate, kidney, bladder, and testis cancers. He has made notable contributions to oncology radiotherapy, particularly in radiobiology.
David holds influential positions at the Montpellier-Nîmes Faculty of Medicine, serving as a University Professor and Hospital Practitioner (exceptional class). He coordinates the Fédération Universitaire d'Oncologie Radiothérapie d'Occitanie Méditerranée (FOROM) and heads the Radiation Oncology Department and serves as the Director of the SIRIC Montpellier Cancer.
He also leads the INSERM radiobiology team at the Institute of Research in Cancerology of Montpellier (IRCM).
David's research focuses on studying healthy tissue toxicity post-radiotherapy. He has made significant progress in developing a blood test to predict radiation treatment side effects. His commitment to enhancing patient care is evident through his coordination of the European clinical radiotoxicity program (REQUITE).
Beyond his roles, David is an elected representative of Continuing Medical Education (CME) on the Board of Directors at the ICM. He actively manages breast, bladder, and prostate cancers and is a member of the urology RCP. He has been the President of the French Society of Radiation Oncology (SFRO) since January 6, 2022.
He is also President of the Réseau Régional d'Onco-Occitanie.
His leadership is evident in his involvement in professional organizations and committees, including the Collège National des Enseignants en Cancérologie.
He founded and chaired UNICANCER's Radiation Oncology Research and Development Group
